Patient's question:
Hello, I would like to know: ABO blood incompatibility. Can we prevent complications before having children?Doctor's answer:
Disease Analysis: Neonatal hemolytic disease caused by ABO blood type incompatibility between mother and child is called "Neonatal Hemolytic Disease due to ABO Blood Type Incompatibility between Mother and Child," referred to as "Neonatal ABO Hemolytic Disease." More than 90% of affected infants have mothers with blood type O and infants with blood type A or B. This ABO blood type incompatibility between mother and child is not uncommon in all pregnancies, accounting for about 20%. However, the occurrence of neonatal hemolytic disease is rare, occurring in only about 1/150, and the symptoms are mostly mild and often overlooked. Only about 1/5 of the infants may develop jaundice. More than 90% of affected infants have mothers with blood type O and infants with blood type A or B. This ABO blood type incompatibility between mother and child is not uncommon in all pregnancies, accounting for about 20%. However, the occurrence of neonatal hemolytic disease is rare, occurring in only about 1/150, and the symptoms are mostly mild and often overlooked. Only about 1/5 of the infants may develop jaundice.Guidance: ABO blood type incompatibility can lead to hemolysis, with 99% occurring in pregnant women with blood type O. When the husband's blood type is A, B, or AB, and the fetus's blood type is A or B, it is more likely to occur. Hemolysis can cause fetal anemia, heart enlargement, hepatosplenomegaly, edema of the fetus and placenta, increased red blood cell count in the blood, and severe cases can lead to fetal hypoxia, resulting in intrauterine fetal death. Newborns may also develop jaundice, and indirect bilirubin can cross the blood-brain barrier, causing the yellowing of brain nerve nuclei, affecting intellectual development and neurological function. Therefore, prenatal blood type testing can help understand the fetal condition early and prepare for monitoring measures for neonatal hemolysis. Additionally, antibody titer tests should be conducted for pregnant women with blood type O. The testing schedule is as follows: the first test at 16 weeks of pregnancy, the second test at 28-30 weeks of pregnancy, and then every 2-4 weeks thereafter. More than half of these pregnant women will develop antibodies after 28 weeks. When the antibody titer is >1:128, it is important to be vigilant about the possibility of hemolysis. Ultrasound examination can also help detect fetal hemolysis. If fetal skin edema, pleural and abdominal effusion, hepatosplenomegaly, or placental enlargement is observed, it should be considered whether maternal-fetal blood type incompatibility is present. Of course, mothers with blood type O should not be too anxious, as not every baby of a blood type O mother will hemolyze, and ABO hemolysis is generally mild. Careful observation of jaundice onset time after birth, early diagnosis, and treatment can lead to a good prognosis. Maternal-fetal blood type incompatibility is a disease that primarily occurs due to blood type incompatibility between the pregnant woman and the fetus, which can cause agglutination and destruction of fetal red blood cells, leading to fetal or neonatal hemolytic disease.
I. Etiology The most common type of maternal-fetal blood type incompatibility is ABO blood type incompatibility. Generally, the pregnant woman is blood type O, and the fetus is blood type A or B, which can lead to neonatal hemolytic disease. ABO blood type incompatibility is relatively common, accounting for about 20-25% of total pregnancies, but only 2-2.5% develop hemolysis, and it is generally mild. This is because fetal tissues contain varying amounts of soluble A or B substances, which can neutralize A and B antibodies. Mild ABO hemolytic disease can be easily confused with physiological jaundice in newborns. Some cases of severe hemolysis progress slowly and may not reach their peak until the 3rd to 5th day after birth. Therefore, you do not need to worry too much; you can still become pregnant, but pay attention to the following issues during pregnancy and after delivery.
II. Laboratory Support Diagnosis for Suspected Blood Type Incompatibility Antibody Testing: Pregnant women with ABO incompatibility should have both partners' blood drawn to determine the immune anti-A or anti-B antibodies in the pregnant woman's blood against her husband's red blood cells and their titer and titer. Titer ≥1:64 is meaningful, and ≥1:512 suggests a more severe condition, requiring hospital treatment. Incomplete Antibody Testing: During early to mid-pregnancy, tests should be conducted every 1-2 months. Between 28-32 weeks of pregnancy, tests should be performed every 2 weeks, and weekly tests should be conducted after 32 weeks of pregnancy. To enhance prenatal care, both partners must check their blood types before pregnancy to detect blood type incompatibility early and prevent treatment.